IPHA — Innate Pharma SA Share News
0.000.00%
Last trade - 00:00- $172.79m
- $159.33m
- €2.79m
Brief: Innate Pharma Announces Preclinical Data With Trifunctional Nk Cell Engager In Acute Myeloid Leukemia
Brief: Sanofi, Innate Pharma Expand Collaboration For Natural Killer Cell Therapeutics In Oncology
Brief: Innate Pharma Presents Data From Ongoing Phase 2 Tellomak Trial Demonstrating Clinical Activity Of Lacutamab In Advanced Sézary Syndrome At Ash 2022
Brief: Innate Pharma 9-Month Revenue Up At Eur 44.3 Mln
Brief: Innate Pharma Presents Data From Ongoing Phase 2 Tellomak Trial
Brief: Innate Pharma H1 Operating Result Turns To Profit Of EUR 8.5 Mln
Innate Pharma slumps as AstraZeneca ends INTERLINK-1 study
Brief: Innate Pharma: AstraZeneca Will Discontinue INTERLINK-1 Phase 3 Study
Brief: Sanofi Selects Innate Pharma's NK Cell Engager As Candidate For Development
Innate Pharma jumps as lung cancer study with AstraZeneca enters phase II
Brief: Innate Pharma Announces IPH5201 Phase 2 Lung Cancer Study With AstraZeneca
Brief: Innate Pharma Q1 Revenue Down At Eur 2.6 Mln
Innate Pharma up as cancer drug trial triggers $50 mln from AstraZeneca
Brief: Innate Pharma Says AstraZeneca Initiated 2nd Phase 3 Monalizumab Trial
Brief: Innate Pharma FY Net Loss Narrows To 52.8 Million Euros
Brief: Innate Pharma Obtains 28.7 Million Euros In State Guaranteed Loans
Brief: Innate Pharma: First Patient Dosed In Clinical Trial In Blood Cancers
Brief: Innate Pharma Updates On Monalizumab Combined With Cetuximab, Durvalumab
Brief: Innate Pharma 9-Month Revenue Down At 10.3 Million Euros